Differentiation syndrome-induced Myopericarditis in the induction therapy of acute Promyelocytic leukemia: a case report.
Acute Promyelocytic leukemia
All trans retinoid acid
Arsenic trioxide
Differentiation syndrome
Myopericarditis
Journal
Cardio-oncology (London, England)
ISSN: 2057-3804
Titre abrégé: Cardiooncology
Pays: England
ID NLM: 101689938
Informations de publication
Date de publication:
23 Nov 2021
23 Nov 2021
Historique:
received:
21
08
2021
accepted:
01
11
2021
entrez:
24
11
2021
pubmed:
25
11
2021
medline:
25
11
2021
Statut:
epublish
Résumé
All trans retinoic acid (ATRA) has revolutionized the treatment and outcomes of patients with Acute Promyelocytic Leukemia (APL). Induction therapy with ATRA is associated with the rare but potentially fatal complication of differentiation syndrome. While the presentation of this syndrome is varied, myopericarditis as a manifestation of differentiation syndrome is often fatal and rarely reported in literature. We present a case of myopericarditis as the sole manifestation of differentiation syndrome in a patient on induction therapy with ATRA and arsenic trioxide for APL. A 62 year old woman with remote history of breast and uterine cancer presented to the hospital for expedited work up of easy bruising and expanding hematomas. She was diagnosed with APL with peripheral blood and bone marrow cytogenetics revealing t (15;17) translocation and initiated on induction therapy with ATRA and ATO as well as steroids for differentiation syndrome prophylaxis. Eighteen days into induction therapy, patient developed pleuritic chest pain, elevated cardiac biomarkers, ECG changes suggestive of pericarditis. Cardiac magnetic resonance imaging showed patchy multifocal sub-epicardial late gadolinium enhancement and elevated T2 signal consistent with acute myopericarditis. Given the timing of symptom onset and lack of other identifiable cause, patient was diagnosed with differentiation syndrome- induced myopericarditis and promptly initiated on high dose steroids with rapid improvement in symptoms, ECG, and cardiac biomarkers. Patient successfully resumed dose-reduced ATRA and arsenic trioxide without complication. Myopericarditis can be the sole manifestation of differentiation syndrome and the presentation may be atypical owing to the use of prophylactic steroids as illustrated in our patient's case. A high index of suspicion for differentiation syndrome, multimodality imaging, and prompt input from multidisciplinary providers is crucial for making the timely diagnosis and initiating life-saving treatment.
Sections du résumé
BACKGROUND
BACKGROUND
All trans retinoic acid (ATRA) has revolutionized the treatment and outcomes of patients with Acute Promyelocytic Leukemia (APL). Induction therapy with ATRA is associated with the rare but potentially fatal complication of differentiation syndrome. While the presentation of this syndrome is varied, myopericarditis as a manifestation of differentiation syndrome is often fatal and rarely reported in literature. We present a case of myopericarditis as the sole manifestation of differentiation syndrome in a patient on induction therapy with ATRA and arsenic trioxide for APL.
CLINICAL PRESENTATION
METHODS
A 62 year old woman with remote history of breast and uterine cancer presented to the hospital for expedited work up of easy bruising and expanding hematomas. She was diagnosed with APL with peripheral blood and bone marrow cytogenetics revealing t (15;17) translocation and initiated on induction therapy with ATRA and ATO as well as steroids for differentiation syndrome prophylaxis. Eighteen days into induction therapy, patient developed pleuritic chest pain, elevated cardiac biomarkers, ECG changes suggestive of pericarditis. Cardiac magnetic resonance imaging showed patchy multifocal sub-epicardial late gadolinium enhancement and elevated T2 signal consistent with acute myopericarditis. Given the timing of symptom onset and lack of other identifiable cause, patient was diagnosed with differentiation syndrome- induced myopericarditis and promptly initiated on high dose steroids with rapid improvement in symptoms, ECG, and cardiac biomarkers. Patient successfully resumed dose-reduced ATRA and arsenic trioxide without complication.
CONCLUSION
CONCLUSIONS
Myopericarditis can be the sole manifestation of differentiation syndrome and the presentation may be atypical owing to the use of prophylactic steroids as illustrated in our patient's case. A high index of suspicion for differentiation syndrome, multimodality imaging, and prompt input from multidisciplinary providers is crucial for making the timely diagnosis and initiating life-saving treatment.
Identifiants
pubmed: 34814948
doi: 10.1186/s40959-021-00124-9
pii: 10.1186/s40959-021-00124-9
pmc: PMC8609250
doi:
Types de publication
Journal Article
Langues
eng
Pagination
39Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
© 2021. The Author(s).
Références
J Cardiovasc Ultrasound. 2011 Jun;19(2):95-8
pubmed: 21860725
Leuk Lymphoma. 2017 Jul;58(7):1743-1746
pubmed: 27919176
Med Pharm Rep. 2019 Oct;92(4):418-420
pubmed: 31750445
N Engl J Med. 2013 Jul 11;369(2):111-21
pubmed: 23841729
Mediterr J Hematol Infect Dis. 2011;3(1):e2011059
pubmed: 22220256
Ann Intern Med. 1992 Aug 15;117(4):292-6
pubmed: 1637024
N Engl J Med. 1997 Oct 9;337(15):1021-8
pubmed: 9321529
J Clin Oncol. 2001 Sep 15;19(18):3852-60
pubmed: 11559723
Ann Hematol. 2007 Dec;86(12):917-8
pubmed: 17619879
Br J Haematol. 2019 Oct;187(2):157-162
pubmed: 31410848
JACC Case Rep. 2020 Nov 18;2(13):2101-2106
pubmed: 34317116